Earnings Call · Q2 FY2026·2026-08-04

Q2 26EPS n/a·Rev n/aQ1 26EPS -49.43%·Rev n/aQ4 25EPS -6.80%·Rev n/aQ3 25EPS +55.32%·Rev n/a⚠ consensus missing

RIGEL PHARMACEUTICALS INC RIGL

Ray Furey — Executive Vice President, General Counsel, and Corporate Secretary

Raul Rodriguez — President and Chief Executive Officer

Dave Santos — Chief Commercial Officer

spk05

Dr. Alison Hannah — Chief Medical Officer

Dean Schorno — Chief Financial Officer

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RIGL calls or request research access.

More RIGL calls Browse calls Request research access